supply of - inj human insulin analogue aspart premix 30 insulin 70 insulin protamine aspart suspension 100 iuml , insulin lispro biphasic injection i.p 25 insulin lispro and 75 insulin lispro , human insulin analogue glargine inj 100 iuml recombinant dna origin 300iu , inj degludec insulin 100 iuml pen , inj degludec insulin aspart recombinant dna origin 70 insulin , human insulin analogue rapid acting inj 100 iu ml , human insulin analogue long acting basal inj 100 iu m , insulin lispro 25 and

The concerned authority has invited bids for the supply of - inj human insulin analogue aspart premix 30 insulin 70 insulin protamine aspart suspension 100 iuml , insulin lispro biphasic injection i.p 25 insulin lispro and 75 insulin lispro , human insulin analogue glargine inj 100 iuml recombinant dna origin 300iu , inj degludec insulin 100 iuml pen , inj degludec insulin aspart recombinant dna origin 70 insulin , human insulin analogue rapid acting inj 100 iu ml , human insulin analogue long acting basal inj 100 iu m , insulin lispro 25 and 75 insulin lispro protamine susp inj 300 iu prefilled pen , insulin premixed biphasic 40 iu per ml 30human neutral plus 70 , insulin highly purified human neutral 40iuml 10 ml inj , inj dulaglutide 1.5 mg , insulin glulisine inj 100 iu ml pen of 3 ml , inj biphasic isophane insulin 5050 , inj insulin isophanenph 50 human - drugs and consumable | quantity - 30. The estimated project cost is ₹3.95 Cr, with an EMD of ₹0.01 Cr. Interested bidders can submit applications until 16 September 2026, with the technical opening scheduled for 16 September 2026.